AKBA announced that the FDA has approved Vafseo (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. HIF PHI$Akebia Therapeutics(AKBA)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
AKBA announced that the FDA has approved Vafseo (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. HIF PHI$Akebia Therapeutics(AKBA)$